290313-23-4 Usage
Uses
Used in Pharmaceutical Industry:
N2-CYCLOPROPYL-2,3-PYRIDINEDIAMINE is used as a building block for the synthesis of biologically active compounds due to its unique structural properties, which contribute to the development of new drugs with potential therapeutic effects.
Used in Medicinal Chemistry Research and Development:
N2-CYCLOPROPYL-2,3-PYRIDINEDIAMINE is utilized as a subject of research and development in medicinal chemistry, where its potential for creating novel therapeutic agents is being explored, particularly in the context of anti-cancer treatments.
Used in Anti-Cancer Treatments:
N2-CYCLOPROPYL-2,3-PYRIDINEDIAMINE is being studied for its potential use in anti-cancer treatments, where it may contribute to the development of new cancer therapies based on its interaction with biological targets relevant to cancer progression and treatment resistance.
Check Digit Verification of cas no
The CAS Registry Mumber 290313-23-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,9,0,3,1 and 3 respectively; the second part has 2 digits, 2 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 290313-23:
(8*2)+(7*9)+(6*0)+(5*3)+(4*1)+(3*3)+(2*2)+(1*3)=114
114 % 10 = 4
So 290313-23-4 is a valid CAS Registry Number.
InChI:InChI=1/C8H11N3/c9-7-2-1-5-10-8(7)11-6-3-4-6/h1-2,5-6H,3-4,9H2,(H,10,11)
290313-23-4Relevant articles and documents
PYRIDOPYRAZINONES DERIVATIVES INSULIN SECRETION STIMULATORS, METHODS FOR OBTAINING THEM AND USE THEREOF FOR THE TREATMENT OF DIABETES
-
Page/Page column 25-26, (2009/10/22)
The present invention relates to pyridopyrazinone derivatives of formula (I), wherein X, Y, Z1 W, A and R1 are as defined in claim 1, as insulin secretion stimulators. The invention also relates to the preparation and use of these pyridopyrazinone derivat
PHARMACEUTICAL COMPOSITION COMPRISING A BENZODIAZEPINE DERIVATIVE AND A INHIBITOR OF THE RSV FUSION PROTEIN
-
Page/Page column 40, (2008/06/13)
A pharmaceutical composition which comprises a pharmaceutically acceptable carrier or diluent and: (a) an inhibitor of the RSV fusion protein; and (b) a benzodiazepine derivative capable of inhibiting RSV replication is found to be highly active against R